The Ledger Now Stands at 1,186
The FDA's active drug shortage list has climbed to 1,186 entries as of this week, a figure that has been trending upward for years despite periodic White House and congressional attention. This is not a single-category crisis. It is a structural condition of the US generic drug market, and it now touches nearly every clinical service line in a hospital, from the operating room to the psychiatric ward to the neonatal ICU.
For sourcing and pharmacy leadership, the number itself matters less than its composition. A shortage list dominated by a handful of exotic biologics would be a manageable problem. A list this size, spread across commodity generics that have been on the market for decades, is a different kind of problem: it means the shortages are being generated by manufacturing economics, not by drug complexity or patent status.
Where the Shortages Cluster
Anesthesia leads the therapeutic categories with 176 active shortages, followed by psychiatry at 155 and pediatric-labeled products at 142. Gastroenterology follows with 87, an unclassified "other" bucket at 75, endocrinology and metabolism at 67, neurology at 59, and oncology at 54. Those eight categories alone account for roughly 815 of the 1,186 total shortages, meaning the remaining 371 or so are distributed across cardiology, infectious disease, hematology, and other services not broken out separately in the top-line count.
The anesthesia and pediatric numbers deserve particular attention because they overlap heavily with sterile injectables: local anesthetics, neuromuscular blockers, parenteral nutrition components, and small-volume injectable formulations dosed by weight for children. These are products where a single plant disruption at a company like Baxter Healthcare, Fresenius Kabi, Hospira or Pfizer can remove meaningful national capacity overnight, because so few manufacturers make them at scale in the first place.
The Amino Acid and Amphetamine Signal
Two examples from this week's list illustrate the pattern well. Baxter Healthcare's Amino Acid Injection, a core building block of parenteral nutrition for patients who cannot be fed enterally, appears repeatedly across multiple NDC-level listings in the current shortage data. Parenteral nutrition shortages are among the most dangerous in medicine because there is no therapeutic substitute; a hospital cannot simply switch a total parenteral nutrition patient to an oral alternative, and compounding pharmacies can only partially fill the gap given raw-material constraints of their own.
Separately, Alvogen's mixed amphetamine salts tablets, the generic version of Adderall and its extended-release analogs, remain in shortage as well. This is a stimulant shortage story that has now run for more than three years nationally, driven by a combination of DEA production quota limits on controlled substances, manufacturing consolidation, and demand that has outpaced the quota system's assumptions. It sits inside the 155-shortage psychiatry category and helps explain why that category ranks second on the entire list, ahead of oncology and neurology combined.
Why This Keeps Happening
The recurring pattern across nearly all 1,186 entries is the same: these are low-margin, off-patent products, often sterile injectables or controlled substances, made by a small number of manufacturers who have little financial incentive to invest in redundant capacity, quality remediation, or backup lines. When one plant has a contamination finding, a recall, or a quota constraint, there is frequently no immediately available second source at scale. FDA's own shortage database repeatedly cites manufacturing and quality issues as the leading root cause category, ahead of demand increases or raw material shortages, and that has been true for over a decade of shortage tracking.
This is a market structure problem, not a manufacturing complexity problem. A generic sterile injectable selling for a few dollars a vial cannot support the kind of multi-site, high-redundancy manufacturing footprint that a $10,000-a-dose biologic can. The economics simply do not fund the resilience hospitals need.
A Playbook for Hospital and Sourcing Teams
Given a list this size and this persistent, reactive purchasing is no longer sufficient. Several concrete steps separate systems that manage shortages well from those that get caught flat-footed.
First, build a tiered risk register that cross-references your formulary against the FDA shortage database and the ASHP shortage list weekly, not monthly. Products in the anesthesia, pediatric, and psychiatry categories should be flagged automatically given their outsized representation on the current list.
Second, diversify wholesaler and manufacturer contracts for high-risk sterile injectables before a shortage hits, not after. Where a product like amino acid injection has only two or three viable US suppliers, a group purchasing organization contract that names a single primary source without a committed secondary source is a latent vulnerability.
Third, maintain active relationships with 503B outsourcing facilities for compounded alternatives to injectable shortages, but treat that as a bridge, not a permanent substitute, given the raw-material constraints that increasingly hit compounders during systemic shortages like the amino acid situation.
Fourth, for controlled substances like the amphetamine products caught in the psychiatry shortage bucket, engage early with the DEA quota process through manufacturer and trade association channels, since quota adjustments lag real-world demand by months.
Fifth, invest in therapeutic interchange protocols reviewed by pharmacy and therapeutics committees in advance of shortages, so that when a neuromuscular blocker or a parenteral nutrition component disappears, clinicians already have an approved, pre-vetted substitution pathway rather than an emergency workaround built under pressure.
What to Watch Next
The 1,186 figure will likely keep drifting rather than dropping sharply in the near term, absent structural reform. Legislative proposals tied to Medicare reimbursement floors for generic sterile injectables, and FDA's continued use of expedited approvals for additional manufacturing sites, are the two levers most likely to move the number. Until either produces measurable capacity additions, hospital pharmacy and sourcing teams should assume that today's shortage list is closer to a baseline operating condition than a temporary anomaly, and plan sourcing strategy accordingly.